Active, not recruitingPHASE1, PHASE2NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Inhibrx Biosciences, Inc
- Principal Investigator
- Clinical LeadInhibrx Biosciences, Inc
- Intervention
- INBRX-106 - Hexavalent OX40 agonist antibody(drug)
- Enrollment
- 296 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (30)
- City of Hope, Duarte, California, United States
- Los Angeles Cancer Network, Glendale, California, United States
- California Research Institute, Los Angeles, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- Valkyrie Clinical Trials, Murrieta, California, United States
- Providence Medical Foundation, Santa Rosa, California, United States
- Clermont Oncology Center, Clermont, Florida, United States
- Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
- Winship Cancer Institute - Emory University, Atlanta, Georgia, United States
- The University of Chicago Medical Center, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Henry Ford Cancer Institute, Detroit, Michigan, United States
- START Midwest, Grand Rapids, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04198766 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →